Oliver Sacks, in a footnote to the case of Christina the Disembodied Lady, noted something that most readers pass over without stopping. Vitamin B6, he observed, in small doses supports the peripheral nervous system. In large doses it produces the precise syndrome that Christina experienced: the progressive loss of proprioception, the dissolution of the body schema, the terrifying sense of a self that can no longer feel where its own limbs are.
The same molecule. Opposite effects. The difference is entirely in the dose.
Sacks filed this observation in a footnote because he had no framework to make it the centre of the argument. The Myelin Mind does. What B6 is doing at low doses and what it is doing at high doses are both myelin stories. The compound that supports the Schwann cells of the peripheral nervous system at one concentration dismantles their work at another. You are not choosing between a helpful supplement and a harmful one. You are choosing a dose on a curve whose two ends produce opposite outcomes, and the curve passes through the biological substance of the self.
This is the organising principle of everything that follows. Natural compounds that interact with the myelination machinery are not supplements in the casual sense. They are interventions in the accumulated biological condition of the organism. Some of them have genuine evidence. Some of that evidence is robust and some is preliminary. But all of them require the same question, asked through a Myelin Mind lens: what is this compound actually doing to the oligodendrocyte, the Schwann cell, the myelin-producing machinery of the nervous system, and at what dose does support become harm?
Vitamin B6
Vitamin B6, pyridoxine, is essential for the synthesis of myelin basic protein, the structural component of the myelin sheath. It is involved in the enzymatic processes that the oligodendrocyte uses to build and maintain the sheath. Deficiency produces peripheral neuropathy. The Schwann cells cannot do their work without adequate B6 and the accumulated condition of the peripheral nervous system begins to thin.
So far, so straightforwardly beneficial.
But at high doses, typically above 200mg per day sustained over months, B6 produces a sensory neuropathy that is clinically indistinguishable from the early stages of Christina’s syndrome. The proprioceptive pathways, the myelinated fibres that carry the body schema from every limb and joint back to the spinal cord and brain, are selectively damaged. The person loses the felt sense of their own body in space. They can see their limbs but cannot feel where they are. They navigate the world by watching themselves from outside rather than inhabiting themselves from within.
The mechanism is not fully understood but the pattern is clear. At low doses B6 supports the myelination machinery. At high doses it overwhelms it, producing toxicity in the very cells it was helping at lower concentrations. The Schwann cell is damaged rather than supported. The sheath thins rather than thickens. The accumulated biological condition of the body schema begins to dissolve.
It is important to say clearly where this risk actually lives. Dietary sources of B6, the nutritional yeast that makes Vegemite what it is, liver, chickpeas, salmon, bananas, do not reach the concentrations that cause harm. The body regulates what it absorbs from food with a precision that the supplement bottle bypasses entirely. No one has ever eaten themselves into peripheral neuropathy via Vegemite. The B6 curve that runs from Christina-preventing to Christina-producing is almost exclusively a supplementation story. The risk lives in the megadose pill, not the kitchen.
This is the B6 curve. And some version of this curve exists for every compound that interacts with the myelination machinery. The question is never simply whether a compound helps. It is where you are on the curve, and whether you are arriving there through food or through a pill.
Saffron
There are accounts of visual recovery following stroke in individuals who incorporated saffron into their daily routine. Such accounts warrant serious attention not because anecdote constitutes evidence, it does not, but because the proposed mechanism is biologically plausible in ways that most natural remedy claims are not.
The active compounds in saffron, principally crocin and crocetin, have been shown in laboratory and animal studies to promote oligodendrocyte survival, protect against myelin damage in models of demyelinating disease, and reduce neuroinflammation in the visual pathway specifically. The visual cortex and the optic pathways are among the most densely myelinated structures in the central nervous system. Ischaemic damage to them, the kind produced by a visual stroke, disrupts myelin and can trigger the inflammatory cascades that further damage the surviving myelin.
Whether saffron drove this man’s recovery, whether spontaneous remyelination occurred alongside his saffron consumption, or whether the two were unrelated, is impossible to determine from his account. Remyelination after ischaemic injury does occur, particularly in younger and otherwise healthy nervous systems, and it occurs on a timeline that could coincide with any intervention introduced in the weeks following the stroke.
What can be said is that the mechanism is not implausible, that the relevant studies are real, and that saffron’s active compounds are doing something at the level of the oligodendrocyte that warrants serious clinical attention. Several trials are currently investigating crocin in MS and other demyelinating conditions. The results will be more informative than any anecdote, however compelling.
The Myelin Mind lens adds one more observation. The visual pathway is not just a heavily myelinated structure. It is a heavily myelinated structure whose accumulated condition is built through a lifetime of visual encounter with the world. Damage to that pathway does not only affect the transmission of visual signals. It disrupts the chiasm between incoming visual signal and the accumulated condition that gives visual experience its meaning. Recovery, if it occurs, is not just the restoration of signal transmission. It is the restoration of the conditions for a particular kind of encounter between the organism and its world.
That is worth pursuing.
The Evidence Landscape
The honest account of natural compounds and myelination requires ranking the evidence rather than treating all claims equally. The Myelin Mind is not a licence for wishful thinking. It is a framework for asking more precise questions. Here is the current state of the evidence, read through that framework.
Vitamin B12 — robust evidence, essential
B12 deficiency produces frank demyelination of the spinal cord and peripheral nervous system. The clinical syndrome, subacute combined degeneration, is a direct myelin story: the Schwann cells and oligodendrocytes cannot maintain the sheath without adequate B12, and the accumulated condition of the myelinated nervous system begins to fail in a predictable sequence. Supplementation in deficient individuals reverses early damage and prevents further loss. This is not preliminary evidence. This is one of the most well-established relationships in clinical neurology.
The caveat is that supplementation beyond adequacy does not produce additional myelination. The oligodendrocyte does not lay down extra myelin because extra B12 is available. It uses what it needs and no more. The B6 curve applies here too: above adequate is not better, it is simply adequate with more compound in circulation.
Vitamin D — robust correlation, mechanism under investigation
The relationship between vitamin D deficiency and multiple sclerosis is one of the most replicated findings in demyelinating disease epidemiology. The further from the equator, the lower the average vitamin D levels and the higher the MS prevalence. The mechanism involves vitamin D receptors on oligodendrocytes and on the immune cells that attack myelin in MS. Low vitamin D appears to reduce oligodendrocyte maturation and to impair the immune regulation that prevents autoimmune demyelination.
Supplementation in deficient individuals is warranted. Whether supplementation in replete individuals provides additional protection is less clear and the trials are ongoing. The curve again: deficiency is harmful, adequacy is protective, excess produces its own problems including hypercalcaemia and vascular calcification that are unrelated to myelination.
Omega-3 fatty acids — strong mechanistic rationale, moderate clinical evidence
Myelin sheaths are largely composed of fatty acids, and DHA, the long-chain omega-3 found in oily fish, is a structural component of the myelin membrane. Oligodendrocytes require adequate DHA to build sheaths of normal composition and thickness. Animal studies show that omega-3 deficiency produces thinner, less effective myelin and that supplementation supports remyelination after injury.
The clinical evidence in humans is more complex because omega-3 status interacts with so many other variables. But the mechanistic rationale is strong, the safety profile at moderate doses is excellent, and the dietary case for adequate oily fish consumption requires no clinical trial to justify. The western diet is chronically low in DHA. That matters for myelination.
Lion’s Mane mushroom — preliminary but interesting
Hericium erinaceus, lion’s mane, contains compounds called hericenones and erinacines that stimulate nerve growth factor and have shown oligodendrocyte-promoting effects in cell culture and animal studies. Several small human trials have shown cognitive benefits in older adults that may reflect improved myelination of the association pathways involved in memory and attention.
The evidence is preliminary. The human trials are small and the mechanisms in humans are not yet clearly established. But the direction of the evidence is consistent and the safety profile appears good. This is a compound worth watching as the trials mature.
Saffron — plausible mechanism, early evidence
As discussed. Biologically plausible, laboratory evidence exists, clinical trials are beginning. Not yet established. Worth attention.
Magnesium — involved in myelination machinery, often deficient
Magnesium is a cofactor in the enzymatic processes of myelin basic protein synthesis. It is also chronically low in many western diets and its deficiency is associated with neurological symptoms that may in part reflect suboptimal myelination. Supplementation to adequacy is well supported. The evidence for supplementation beyond adequacy in myelination is not established.
Melatonin — emerging evidence, relevant to sleep
The relationship between melatonin, sleep and myelination connects to the Myelin Mind thesis on sleep as the editing phase of the chiasm. Melatonin has shown neuroprotective and remyelinating effects in several animal models, and its role in regulating the sleep that drives myelin consolidation makes it mechanistically interesting. The direct evidence for melatonin supplementation producing remyelination in humans is not yet established.
A question of moderation: when healing become harm
The B6 case is not unique. Several natural compounds that are generally understood as beneficial have myelin-disrupting effects at high doses or in specific contexts.
Hexane and certain industrial solvents produce demyelination through direct Schwann cell toxicity. These are not supplements but they appear in some essential oil preparations and industrial herbal extracts at concentrations that warrant attention.
High dose vitamin E has been associated with impaired myelin formation in some contexts, possibly through interference with vitamin K-dependent processes involved in oligodendrocyte function.
Excessive liquorice root contains glycyrrhizin which affects adrenal hormone metabolism and can produce a syndrome including peripheral neuropathy at high doses, likely involving Schwann cell function.
St John’s Wort at high doses has complex interactions with neurological medications including those used to manage MS, and its effects on the myelination machinery are not well studied.
The principle here is not that natural is dangerous. It is that natural compounds that interact with the myelination machinery do so with the same biological specificity as pharmaceutical compounds, and that the dose-response curve for these interactions is rarely a simple more-is-better relationship.
Reading the curve
The Myelin Mind account of natural compounds and myelination produces a single clinical principle that is more useful than any list of supplements.
Every compound that interacts with the myelination machinery sits on a curve. On one part of that curve it supports the oligodendrocyte and the Schwann cell. On another part it overwhelms them, competes with essential processes, or produces toxicity in the cells it was previously helping. The position on the curve is determined by dose, by the individual’s existing nutritional status, by the specific pathways involved, and by the particular vulnerability of the nervous system at that moment in the person’s life.
Christina’s syndrome can be produced by excess of the very compound that prevents it. This is not a pharmacological curiosity. It is a statement about the precision required when intervening in the biological substance of the self.
The accumulated myelinated condition is not a database that can be upgraded with the right inputs. It is a biological structure built slowly, at metabolic cost, by cells that are doing extraordinarily precise work. Compounds that support that work do so within a range. Exceed that range and you are no longer supporting the structure. You are introducing noise into the most precise biological process available to the organism.
The question to ask of any natural compound that claims to support myelination is not whether it helps. Ask at what dose it helps, at what dose it becomes irrelevant, and at what dose it harms. The answer to all three questions is biological, not philosophical, and the evidence for each part of the answer varies from robust to preliminary to unknown.
Start with the robust. Maintain adequacy of B12, vitamin D, omega-3. Pursue the preliminary with appropriate caution and appropriate doses. And remember that those who report recovery after introducing saffron or other compounds may have been helped by them, or may have recovered through the nervous system’s own remyelination capacity, or may have recovered partly because they were paying close attention to their own nervous system for the first time.
Paying close attention to your own nervous system is not a supplement. But it may be the most underrated intervention available.
Jack Parry is a philosopher, polyglot and biomedical animator at Swinburne University of Technology. He is the author of The Myelin Mind: The Genesis of Meaning